Study summary
Osimertinib after chemoradiation kept stage III lung cancer in check for years
39.1months without progression, vs 5.6 with placebo
What was tested
Osimertinib against placebo in people with unresectable stage III EGFR-mutated lung cancer whose disease had not grown after chemotherapy and radiation.
What they found
- Median progression-free survival was 39.1 months vs 5.6 months.
- Radiation pneumonitis, mostly mild, occurred in 48% vs 38%.
What it means
Made osimertinib a standard follow-on treatment after chemoradiation for stage III disease.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.